Switch theme
Sign up to access all valuation multiples
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
1993
94
LTM Revenue $81.9M
LTM EBITDA $14.3M
$183M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Theratechnologies has a last 12-month revenue (LTM) of $81.9M and a last 12-month EBITDA of $14.3M.
In the most recent fiscal year, Theratechnologies achieved revenue of $85.9M and an EBITDA of $6.9M.
Theratechnologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Theratechnologies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $81.9M | XXX | $85.9M | XXX | XXX | XXX |
| Gross Profit | $64.9M | XXX | $65.4M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $14.3M | XXX | $6.9M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $6.2M | XXX | $8.2M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | -$2.9M | XXX | -$8.3M | XXX | XXX | XXX |
| Net Margin | -4% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $38.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Theratechnologies's stock price is $3.
Theratechnologies has current market cap of $150M, and EV of $183M.
See Theratechnologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $183M | $150M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Theratechnologies has market cap of $150M and EV of $183M.
Theratechnologies's trades at 2.1x EV/Revenue multiple, and 25.1x EV/EBITDA.
Equity research analysts estimate Theratechnologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Theratechnologies has a P/E ratio of -52.1x.
See valuation multiples for Theratechnologies and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $150M | XXX | $150M | XXX | XXX | XXX |
| EV (current) | $183M | XXX | $183M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 12.8x | XXX | 25.1x | XXX | XXX | XXX |
| EV/EBIT | 29.4x | XXX | 23.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -52.1x | XXX | -19.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -27.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTheratechnologies's last 12 month revenue growth is 8%
Theratechnologies's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.
Theratechnologies's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Theratechnologies's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Theratechnologies and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 50% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 67% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theratechnologies acquired XXX companies to date.
Last acquisition by Theratechnologies was XXXXXXXX, XXXXX XXXXX XXXXXX . Theratechnologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Theratechnologies founded? | Theratechnologies was founded in 1993. |
| Where is Theratechnologies headquartered? | Theratechnologies is headquartered in United States of America. |
| How many employees does Theratechnologies have? | As of today, Theratechnologies has 94 employees. |
| Who is the CEO of Theratechnologies? | Theratechnologies's CEO is Mr. Paul Levesque. |
| Is Theratechnologies publicy listed? | Yes, Theratechnologies is a public company listed on NAS. |
| What is the stock symbol of Theratechnologies? | Theratechnologies trades under THTX ticker. |
| When did Theratechnologies go public? | Theratechnologies went public in 2010. |
| Who are competitors of Theratechnologies? | Similar companies to Theratechnologies include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Theratechnologies? | Theratechnologies's current market cap is $150M |
| What is the current revenue of Theratechnologies? | Theratechnologies's last 12 months revenue is $81.9M. |
| What is the current revenue growth of Theratechnologies? | Theratechnologies revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Theratechnologies? | Current revenue multiple of Theratechnologies is 2.2x. |
| Is Theratechnologies profitable? | Yes, Theratechnologies is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Theratechnologies? | Theratechnologies's last 12 months EBITDA is $14.3M. |
| What is Theratechnologies's EBITDA margin? | Theratechnologies's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Theratechnologies? | Current EBITDA multiple of Theratechnologies is 12.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
